What Is Cagri?
Type Long-acting Amylin Receptor Agonist CAS Number 1266112-39-2 Molecular Weight ~6,880 g/mol Molecular Weight (Cu) N/A Amino Acids 37 Amino Acids (Modified synthetic analog) Sequence Modified non-selective amylin receptor agonist sequence
Stability Information
High-purity synthetic amylin analogLyophilized powder (white/off-white)Protected from light and moisture Lyophilized (powder) –20 °C · up to 2 years Reconstituted 2-8 °C · up to 30 days
About Cagri
Cagrilintide is a synthetic amylin analog peptide developed for research involving energy balance, appetite regulation, and metabolic control. It acts as a long-acting amylin receptor agonist, providing a valuable research model for studying satiety signaling, body-weight regulation, and glucose metabolism. Cagrilintide is often used in combination research with incretin-based peptides such as GLP-1 receptor agonists, enabling the exploration of multi-pathway peptide synergy in metabolic and endocrine studies. This high-purity lyophilized powder is intended strictly for laboratory research by qualified professionals.
Mechanism of Action
The mechanism involves Cagrilintide acting as a potent agonist for the amylin receptors, primarily in the hindbrain (area postrema). By activating these receptors, it triggers central satiety signals that reduce energy intake. Additionally, it slows gastric emptying, which prolongs the absorption of nutrients and contributes to the regulation of postprandial glucose. In combination studies, it is investigated for its ability to complement GLP-1 receptor pathways, targeting multiple biological axes to study energy homeostasis and lipid metabolism.
What Research Has Shown
Metabolic Research 98 Purity Percentage (HPLC verified) Synergistic Satiety Signaling Cagrilintide + GLP-1 Analog 94.5% Amylin Agonist Monotherapy 65.0% Trial details: Investigative studies examining energy expenditure, appetite suppression, and glucose regulation in experimental endocrine research models. Satiety Results
Appetite Regulation & Weight Homeostasis
Findings from amylin receptor agonism investigations
92% Satiety Signaling Enhanced Hypothalamic Activation 86% Gastric Emptying Significantly Delayed Digestion Note: Results highlight Cagrilintide’s potential in studying multi-pathway synergy for body-weight regulation.
Research Highlights
Amylin Receptor Agonism
Research focusing on the binding dynamics of long-acting synthetic amylin analogs.
Multi-Pathway Peptide Synergy
Investigating the combination of incretin and amylin pathways for metabolic regulation.
Energy Expenditure Dynamics
Studies exploring how receptor agonism influences resting energy balance and appetite suppression.
Pharmacological Signaling Profiling
Exploration of biochemical signaling and peptide behavior in endocrine and metabolic assay models.
Product Specifications
- Molecular Formula
- C₆₂H₉₈N₁₆O₂₂
- Molecular Weight
- 1419.53 g/mol
- Sequence
- Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
- Purity
- ≥99% (HPLC verified)
- Form
- Lyophilized powder
- Appearance
- White to off-white powder
- Solubility
- Soluble in water, bacteriostatic water
- Storage
- -20°C (lyophilized), 2-8°C (reconstituted)
Research Studies
A Novel Long-Acting Amylin Analog in Metabolic Research
A comprehensive analysis of amylin receptor signaling and its impact on body-weight regulation.
Kruse T. & Hansen J.L. View Full Study
Frequently Asked Questions
What is the primary mechanism of Cagrilintide in metabolic research?
It acts as a long-acting amylin receptor agonist, modulating satiety-related pathways and slowing gastric emptying.
Why is it frequently studied alongside GLP-1 agonists?
Research focuses on the synergy between the amylin and incretin pathways to investigate a multi-pathway approach to energy balance and glucose metabolism.
Related products
